Clinical Trial Update: A RTC to Examine the Effectiveness of 400 mg of Oral Zinc Gluconate as Adjunctive Therapy for Ano-genital Warts [Phase 4]

View source ↗

Summary

Phase 4 randomized trial evaluating 400 mg of oral zinc gluconate as adjunctive therapy for genital warts (HPV-related) was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Genital Warts
• Human Papillomavirus Infection

Drugs mentioned

• Zinc gluconate (zinc gluconate)

Snippet

Sponsor: University of British Columbia | Conditions: Genital Warts, HPV | Phase 4 | Status: TERMINATED